Selected article for: "active ingredient and acute sars respiratory syndrome"
Author: Shen, Xuhui; Yin, Fugen
Title: The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule
  • Cord-id: qeo0sr9t
  • Document date: 2021_8_9
    • ID: qeo0sr9t
    Snippet: Lianhua-Qingwen capsule (LQC) is a commonly used Traditional Chinese Medicine (TCM) in China and has 11 herb components. The main active ingredient can target specific molecules and perform many clinic treatment roles. LQC has been authorized by National Medical Products Administration (NMPA) of China to treat severe acute respiratory syndrome (SARS) in 2002–2003, type A influenza virus HIN1 pandemic in 2009, H7N9, H3N2 and coronavirus disease-19 (COVID19) caused by severe acute respiratory sy
    Document: Lianhua-Qingwen capsule (LQC) is a commonly used Traditional Chinese Medicine (TCM) in China and has 11 herb components. The main active ingredient can target specific molecules and perform many clinic treatment roles. LQC has been authorized by National Medical Products Administration (NMPA) of China to treat severe acute respiratory syndrome (SARS) in 2002–2003, type A influenza virus HIN1 pandemic in 2009, H7N9, H3N2 and coronavirus disease-19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in 2020. It is also widely used to treat common cold with wind-heat syndrome, chronic rhinosinusitis (CRS), amygdalitis and chronic obstructive pulmonary disease. This article summarizes the advanced research progress of LQC in clinical application, mechanisms and provides new clues in the clinical application of LQC.

    Search related documents:
    Co phrase search for related documents
    • acidic environment and acute lung injury: 1
    • acidic environment and acute respiratory distress syndrome: 1
    • acidic environment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activated protein kinases and acute ards respiratory distress syndrome: 1
    • activated protein kinases and acute lung injury: 1, 2, 3, 4, 5, 6, 7
    • activated protein kinases and acute respiratory distress syndrome: 1, 2
    • activated protein kinases and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • active ingredient and acute ards respiratory distress syndrome: 1
    • active ingredient and acute ards respiratory distress syndrome progress: 1
    • active ingredient and acute lung injury: 1, 2
    • active ingredient and acute respiratory distress syndrome: 1
    • active ingredient and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active ingredient and lonicera japonica: 1
    • active ingredient and lonicerae japonicae: 1
    • acute ards respiratory distress syndrome and low affinity: 1
    • acute lung injury and lonicera japonica: 1
    • acute lung injury and lonicerae japonicae: 1
    • acute lung injury and low affinity: 1, 2, 3
    • acute respiratory distress syndrome and low affinity: 1